Active substanceCocarboxylaseCocarboxylase
Similar drugsTo uncover
  • Cocarboxylase
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Cocarboxylase
    lyophilizate w / m 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase-Ferein
    lyophilizate w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cocarboxylase-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
  • Cocarboxylase hydrochloride
    lyophilizate w / m in / in 
  • Dosage form: & nbsp

    lyophilizate for the preparation of a solution for intravenous and intramuscular administration.

    Composition:

    Composition per 1 ampoule:

    active substance: cocarboxylase hydrochloride - 50.0 mg; adjuvant: sodium carbonate - 8.0 mg.

    Description:

    Liofilizirovannaya dry porous hygroscopic mass of white color, with a weak specific odor.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.11.D.A   Vitamin B1

    Pharmacodynamics:

    Kokarboksilaza - coenzyme thiamine (vitamin B1), in the body phosphorylated to form mono-, di- and tri-phosphoric esters, is part of the enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids, pyruvic acid. Endogenous cocarboxylase is formed in the body from exogenous thiamin by phosphorylation, however, the properties of cocarboxylase do not fully correspond to the properties of thiamine and it can not be used for the prevention and treatment of hypo- and avitaminosis B1. Cocarboxylase improves the absorption of glucose, trophic nervous tissue, contributes to the normalization of the function of the cardiovascular system. Reduces the level of lactic and pyruvic acid in the blood (increasing the content of these acids leads to the development of acidosis and acidosis).

    Indications:

    Cocarboxylase is prescribed as a part of complex therapy for hepatic and renal insufficiency, diabetic precoma and coma, diabetic ketoacidosis, chronic heart failure and cardiac rhythm disturbances, peripheral neuritis.

    Children prescribe the drug for the same indications. In children during the newborn period, the drug is also used as part of complex therapy of conditions accompanied by hypoxia and acidosis, including asphyxia of newborns, perinatal hypoxic encephalopathy, circulatory insufficiency, pneumonia, sepsis.

    Contraindications:

    Hypersensitivity to the components of the drug.

    Pregnancy and lactation:

    Due to the insufficient number of studies, the drug should not be given to pregnant and lactating women.

    Dosing and Administration:

    Kokarboksilazu injected intramuscularly or intravenously (struino or drip).

    If heart rhythm disturbances are prescribed, 100-200 mg / day for 15-30 days.

    In chronic heart failure: 50 mg 2 hours before the use of digitalis preparations 2-3 times a day.

    In diabetes (ketoacidosis, coma), the daily dose is 100 mg.

    In acute renal and hepatic insufficiency intravenously injected 100-150 mg 3 times a day or drip (previously dissolved in a 5% solution of dextrose (glucose)) at 100-150 mg / day.

    With peripheral neuritis, intramuscularly administered at a dose of 50-100 mg / day for 1-1.5 months.

    Children injected intramuscularly, intravenously (by drip or jet). Depending on the severity and clinical symptoms appointed from 25 to 50 mg / day. The course of treatment is from 3-7 to 15-30 days. The newborn is administered intravenously (slowly) 10 mg / kg once a day.

    Preparation of solutions

    For intramuscular administration, the contents of the ampoule (50 mg) are dissolved immediately before administration to 2 ml of water for injection.

    For intravenous fluid administration, the volume of the solution is adjusted to 10-20 ml, for drip administration - up to 200-400 ml, adding a 0.9% solution of sodium chloride or a solution of dextrose.

    Side effects:

    Allergic reactions (hives, itching); when intramuscular injection - hyperemia, edema at the injection site.

    Overdose:

    There is no information on overdose.

    Interaction:

    Kokarboksilaza increases the cardiotonic action of cardiac glycosides and improves their tolerability.

    Effect on the ability to drive transp. cf. and fur:

    The effect of the drug on the ability to drive vehicles and mechanisms has not been studied.

    Form release / dosage:

    Lyophilizate for the preparation of solution for intravenous and intramuscular injection 50 mg.

    Packaging:

    1. For 50 mg in ampoules with a capacity of 2, 3 or 5 ml of glass grade HC-1, or HC-3, or glass 1 hydrolytic class.

    2. a) 5 ampoules with the preparation and 5 ampoules with water for injection 2 ml each are placed in separate contoured cell packs made of a polyvinyl chloride film.

    1 contour mesh package with the preparation and 1 circuit cell pack with water for injection with instructions for use are placed in a pack of cardboard.In the pack put knife ampoule or scarifier.

    b) 5 ampoules with a preparation complete with 5 ampoules of water for injections of 2 ml are placed in a contour mesh package made of a polyvinyl chloride film.

    1 circuit cell pack with instructions for use is placed in a pack of cardboard. In the pack put knife ampoule or scarifier.

    When using ampoules with a break ring or notch and a point, the ampoule knife or scarifier is not inserted.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001545
    Date of registration:19.10.2011 / 28.12.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:Company DEKO, LLC Company DEKO, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up